Treatment Capacity Dominance 

Treatment capacity dominance arises where a healthcare provider, hospital group, specialist treatment centre, diagnostic network, or similar undertaking controls such a substantial share of the available capacity for a particular treatment that patients, insurers, governments, or other healthcare providers have limited realistic alternatives.

In competition law, having large treatment capacity is not unlawful by itself. The concern begins when control over scarce capacity gives an undertaking substantial market power and that position is used to impose unfair conditions, exclude competitors, restrict access, discriminate between customers, or extend market power into related healthcare markets.

The concept is particularly relevant where treatment requires scarce infrastructure such as intensive-care beds, specialist surgical facilities, dialysis capacity, radiotherapy equipment, transplant facilities, specialist doctors, or highly specialised diagnostic services.

1. Meaning of Treatment Capacity Dominance

Treatment capacity refers to the amount of healthcare service that a provider can realistically supply during a particular period. It may be measured through available beds, operating theatres, treatment slots, specialist staff, machines, geographic coverage, or the number of patients that can safely be treated.

A provider may acquire substantial market power where it controls a large proportion of this capacity and rivals cannot expand quickly.

For example, suppose a region has only three hospitals capable of providing a specialised treatment. If one hospital controls most specialist doctors, treatment equipment and available treatment slots, patients may have few realistic alternatives even though other hospitals technically exist.

Competition authorities would normally examine whether the provider can behave to an appreciable extent independently of competitors, patients and purchasers.

2. Relevant Market

The first major question is defining the relevant product and geographic market.

A broad market such as "healthcare services" may hide significant market power. Authorities may instead consider a narrower market such as specialist cardiac surgery, oncology treatment, dialysis, inpatient super-speciality treatment, or another treatment that patients cannot realistically substitute.

Geography is equally important. A treatment centre located hundreds of kilometres away may not provide a meaningful competitive alternative, particularly where treatment is urgent or requires repeated visits.

The Competition Commission of India (CCI), for example, has considered whether super-speciality hospital services and even services supplied to patients after admission could constitute relevant markets. Its 2026 hospital decisions emphasise that the relevant market cannot simply be defined so narrowly that a hospital automatically becomes dominant merely because a patient has already entered that hospital.

3. Capacity as Evidence of Dominance

Market share remains important, but capacity can sometimes reveal market power more accurately than revenue.

Authorities may examine the proportion of available specialist beds or treatment slots controlled by the undertaking, utilisation rates, waiting lists, ability of competitors to expand capacity, access to specialists and medical equipment, regulatory approvals, investment requirements, and patient switching possibilities.

High capacity utilisation can make the issue particularly important. If competing hospitals are already operating close to their limits, their theoretical presence may provide little competitive constraint on a dominant provider.

Under Indian competition law, Section 19(4) of the Competition Act contains factors relevant to assessing dominance. Recent CCI hospital proceedings also demonstrate that dominance must actually be established through competitive analysis rather than simply presumed from the patient's relationship with an individual hospital.

4. Barriers to Expansion

Treatment capacity can be difficult to reproduce.

A competitor may need regulatory approvals, substantial capital investment, specialised buildings, expensive equipment, trained doctors and nurses, accreditation, insurer relationships and years of reputation building.

Consequently, even high treatment prices may not immediately attract new capacity.

This distinguishes healthcare capacity from markets where competitors can rapidly increase production.

5. Capacity Hoarding or Strategic Underutilisation

A potentially serious competition issue occurs where a dominant undertaking deliberately controls or withholds scarce capacity for strategic rather than legitimate medical or operational reasons.

Examples could include reserving treatment slots unnecessarily, preventing independent specialists from accessing facilities, acquiring scarce capacity principally to prevent rival expansion, or entering exclusivity arrangements covering critical facilities.

However, unused capacity does not automatically establish abuse. Hospitals legitimately maintain reserve capacity for emergencies, infection control, maintenance, staffing requirements and unpredictable demand.

The competition authority therefore has to distinguish legitimate clinical capacity management from exclusionary conduct.

6. Refusal of Access

Control over treatment capacity can also produce refusal-to-supply or access questions.

Suppose a vertically integrated healthcare group owns the only practically available specialist treatment infrastructure in an area. If independent doctors or downstream healthcare businesses require access to that infrastructure, an unjustified refusal could potentially restrict downstream competition.

Competition analysis would consider whether the facility is genuinely indispensable, whether realistic alternatives exist, whether additional capacity can reasonably be constructed, and whether there is an objective justification for restricting access.

7. Discriminatory Allocation of Capacity

A dominant provider may also create concerns if comparable customers receive materially different access conditions without legitimate justification.

For example, capacity might theoretically be allocated preferentially to affiliated businesses while competing healthcare providers receive inferior treatment slots.

But healthcare requires particularly careful analysis because different treatment decisions can legitimately reflect clinical urgency, patient condition, specialist availability and medical risk.

Therefore, different treatment or scheduling alone does not demonstrate competition-law discrimination.

8. Excessive Pricing and Captive Patients

Capacity shortages can increase bargaining power.

Once a patient has been admitted, switching hospitals may become difficult because of medical condition, transportation risks, existing treatment, doctor relationships and urgency.

This creates the possibility of an aftermarket or lock-in theory.

The CCI's recent Delhi hospital cases examined allegations involving room charges, diagnostic tests, medicines, medical devices and consumables supplied to admitted patients. The Director General had treated individual hospitals as effectively dominant over their admitted patients in certain proposed aftermarket definitions. The Commission ultimately rejected the abuse findings on the evidence and criticised important aspects of the market-definition and pricing methodology.

The cases therefore demonstrate an important principle: patient lock-in can be relevant, but it does not automatically establish either dominance or abusive pricing.

9. Capacity and Mergers

Treatment capacity is also important in merger control.

If two major hospital groups combine, revenue-based market shares alone may not reveal the transaction's full competitive significance. Authorities can examine how much specialist capacity disappears as an independent competitive constraint.

Potential concerns include reduced available alternatives, increased negotiating power against insurers, reduced competition for doctors, longer waiting periods, or weaker incentives to expand treatment capacity.

At the same time, mergers can produce legitimate efficiencies—for example, combining specialist teams or improving utilisation of expensive medical infrastructure. Such claims require evidence.

Important Case Laws

1. Vivek Sharma v. St. Stephen's Hospital — CCI, 21 May 2026

This is particularly relevant to healthcare dominance.

The investigation examined whether the hospital could be treated as dominant in relation to admitted patients and whether charges for rooms, tests, medical devices, medicines and consumables constituted abusive pricing.

The CCI ultimately concluded that the evidence did not establish abuse under Section 4. It also applied the principles associated with the United Brands excessive-pricing test and found the necessary requirements unestablished.

Relevance: Capacity or patient dependence cannot simply be converted into an assumption of dominance. Market definition, competitive alternatives and evidence of abuse remain necessary.

2. Vivek Sharma v. Sir Ganga Ram Hospital — CCI, 21 May 2026

The DG had proposed a market relating to healthcare facilities for in-patients admitted to the particular hospital and found dominance and abusive pricing.

The hospital challenged that approach as excessively narrow. The CCI ultimately closed the Section 4 case and rejected the proposition that the evidence established abusive pricing.

Relevance: A provider should not automatically be declared dominant merely because an admitted patient faces practical switching difficulties.

3. Vivek Sharma v. Fortis Flt. Lt. Rajan Dhall Hospital, Vasant Kunj — CCI, 21 May 2026

The supplementary investigation considered whether Fortis was dominant in healthcare services supplied to its admitted patients and whether prices charged for associated products and services constituted abuse.

Arguments concerning alternative hospitals, patient switching and the Section 19(4) dominance factors formed part of the competitive assessment.

Relevance: The case demonstrates why treatment capacity must be considered alongside realistic competitive alternatives rather than treated as conclusive evidence of dominance.

4. Vivek Sharma v. Indraprastha Medical Corporation Ltd. (Indraprastha Apollo Hospital) — CCI, 21 May 2026

This proceeding formed part of the wider investigation originating from allegations concerning hospital-supplied medical products and possible aftermarket abuse.

The broader investigation considered whether admitted patients became sufficiently locked into individual hospitals for each hospital effectively to possess market power over complementary products and services.

Relevance: Treatment capacity can create economic dependence after admission, but establishing a legally relevant aftermarket requires careful evidence concerning switching and substitutability.

5. Vivek Sharma v. Max Super Specialty Hospital, Shalimar Bagh — CCI, 21 May 2026

The DG found dominance in a proposed market concerning healthcare facilities supplied to admitted patients and alleged abusive pricing of associated hospital products and services.

The Commission's analysis addressed the distinction between the broader super-speciality hospital market and the proposed hospital-specific aftermarket.

Relevance: Treatment capacity analysis depends heavily upon how the relevant market is constructed. Artificially defining every hospital as its own market risks making dominance automatic rather than proving it through competitive conditions.

6. United Brands Company v. Commission — European Court of Justice, Case 27/76

This is one of the foundational abuse-of-dominance cases.

The Court established an influential approach to excessive pricing: consideration may be given to whether the difference between costs and price is excessive and, if so, whether the resulting price is unfair in itself or compared with competing products.

The CCI expressly discussed the United Brands framework in its 2026 hospital proceedings and concluded that the evidence before it did not satisfy the required tests.

Relevance: If control over scarce treatment capacity allegedly permits extremely high prices, competition authorities still need economic evidence establishing that the prices are legally abusive rather than merely expensive.

7. Hoffmann-La Roche & Co. AG v. Commission — European Court of Justice, Case 85/76

This leading dominance case explains dominance as a position of economic strength allowing an undertaking to prevent effective competition and behave to an appreciable extent independently of competitors, customers and ultimately consumers.

Relevance: The principle fits treatment-capacity cases directly. The fundamental question is whether control of treatment infrastructure gives the provider substantial independence from normal competitive constraints.

8. Bronner v. Mediaprint — European Court of Justice, Case C-7/97

Bronner established a demanding framework concerning compulsory access to infrastructure controlled by a dominant undertaking.

A claimant cannot normally establish abuse merely because access to another undertaking's facility would make competition easier. The absence of realistic alternatives and the practical possibility of creating alternative infrastructure are highly important.

Relevance: Where competitors demand access to a dominant hospital's specialist treatment infrastructure, the fact that constructing competing capacity is expensive does not automatically make the existing facility legally indispensable.

Competition-Law Assessment

A treatment-capacity dominance investigation can therefore be understood as a sequence:

Relevant treatment market → geographic market → available treatment capacity → provider's share of capacity → rival spare capacity → barriers to expansion → patient switching → bargaining power → allegedly abusive conduct → objective justification → competitive effects.

The strongest cases generally require more than evidence that one hospital is large. Authorities need to establish both dominance and abuse.

Dominance may arise from control of scarce beds, specialists, equipment or treatment slots combined with significant entry barriers. Potential abuse may then involve exclusionary denial of access, discriminatory capacity allocation, restrictive exclusivity, tying, unfair contractual conditions or, under demanding legal standards, excessive pricing.

Conclusion

Treatment capacity dominance is therefore primarily a scarcity and market-power problem. A hospital or specialist provider can become especially important where rivals cannot expand quickly and patients have limited substitutes. But large capacity, high utilisation, high prices or patient dependence do not individually prove an infringement.

The 2026 CCI hospital decisions are particularly instructive: they show that even where patients may become relatively dependent after admission, competition authorities must still establish a defensible relevant market, actual dominance and legally sufficient evidence of abusive conduct.